Okrelizumab – ważna opcja terapeutyczna w leczeniu chorych na stwardnienie rozsiane – analiza doniesień z Kongresu Amerykańskiej Akademii Neurologii – stan wiedzy z 2019 r. Raport konferencyjny
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
cze 30, 2019
Słowa kluczowe:
stwardnienie rozsiane, terapia immunomodulacyjna, przeciwciała monoklonalne, okrelizumab
##plugins.themes.bootstrap3.article.main##
Abstrakt
W pracy dokonano przeglądu doniesień prezentowanych w trakcie dorocznego Kongresu Amerykańskiej Akademii Neurologii obejmujących terapię stwardnienia rozsianego z zastosowaniem okrelizumabu.
Na podstawie przeglądu można stwierdzić, że leczenie okrelizumabem jest wysoce skuteczne, a jego profil bezpieczeństwa nie budzi większych wątpliwości. Obecnie jest to jedyny lek zarejestrowany do leczenia postaci pierwotnie przewlekle postępującej stwardnienia rozsianego.
##plugins.themes.bootstrap3.article.details##
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Charakterystyka Produktu Leczniczego. Ocrevus [online] .
2. Montalban X, Hauser SL, Kappos L et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med 2017; 376(3): 209-220.
3. Hauser SL, Bar-Or A, Comi G et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med 2017; 376(3): 221-234.
4. Leist T, Reder A, Bermel R et al. One-year interim analysis results of the Phase IIIb CHORDS study evaluating ocrelizumab effectiveness and safety in patients with relapsing-remitting multiple sclerosis who had suboptimal response with prior disease-modifying treatments. Presented at: AAN Annual Meeting 2019; May 7, 2019; Philadelphia, PA, USA. Abstract: S56-007.
5. Cross A, Bennett J, von Büdingen HC et al. Ocrelizumab treatment reduced levels of neurofilament light chain and numbers of B cells in the cerebrospinal fluid of patients with relapsing multiple sclerosis in the OBOE study. Presented at: AAN Annual Meeting 2019; May 7, 2019; Philadelphia, PA, USA. Abstract. S56-008.
6. Naismith R, Coyle P, Saidha S et al. Influence of Gender and Age in Use of Ocrelizumab for PPMS Patients Among US Neurologists. Presented at: AAN Annual Meeting 2019; May 7, 2019; Philadelphia, PA, USA. Abstract P1.2-102.
7. Wolinsky J, Kappos L, Montalban X, Model F. Reduction in 48-Week Confirmed Disability Progression After 5.5 Years of Ocrelizumab Treatment in Patients With Primary Progressive Multiple Sclerosis. Presented at: AAN Annual Meeting 2019; May 7, 2019; Philadelphia, PA, USA. Abstract S3.2-031.
8. Arnold DL, Giovannoni G, Hartung HP et al. Reduced Rate of Brain Atrophy in Patients With PPMS Receiving Ocrelizumab Earlier and Continuously Versus Those Initiating Okrelizumab Later: Results of ORATORIO 5-Year Follow-Up. Presented at: AAN Annual Meeting 2019; May 7, 2019; Philadelphia, PA, USA. Abstract P3.2-042.
9. Hauser SL, Kappos L, Montalban X et al. Long-Term Reduction in 48-Week Confirmed Disability Progression After 5 Years of Ocrelizumab Treatment in Patients With Relapsing Multiple Sclerosis. Presented at: AAN Annual Meeting 2019; May 7, 2019; Philadelphia, PA, USA. Abstract P3.2-054.
10. Giovannoni G, Airas L, Bove R et al. Ocrelizumab Treatment Effect on Upper Limb Function in PPMS Patients with Disability: Subgroup Results of the ORATORIO Study to Inform the ORATORIO-HAND Study Design. Presented at: AAN Annual Meeting 2019; May 7, 2019; Philadelphia, PA, USA. Abstract P3.2-091.
11. Kletzl H, Gibiansky E, Petry C et al. Pharmacokinetics, Pharmacodynamics and Exposure-Response Analyses of Ocrelizumabein Patients With Multiple Sclerosis. Presented at: AAN Annual Meeting 2019; May 7, 2019; Philadelphia, PA, USA. Abstract N4-001.
12. Vollmer T, Alvarez E, Nair K et al. Evaluation of shorter infusion times with ocrelizumabin patients with relapsing-remitting multiple sclerosis. Presented at: AAN Annual Meeting 2019; May 7, 2019; Philadelphia, PA, USA. Abstract P3.2-034.
13. Alimohamadi S, Vollmer B, Nair K et al. Ocrelizumab Safety and Effectiveness in the One Year Treatment of Multiple Sclerosis Compared to Other Disease Modifying Therapies. Presented at: AAN Annual Meeting 2019; May 7, 2019; Philadelphia, PA, USA. Abstract P3.2-053.
14. Moss B, Parrotta E, Baldassari L et al. Real-World Experience with Ocrelizumab. Presented at: AAN Annual Meeting 2019; May 7, 2019; Philadelphia, PA, USA. Abstract P3.2-059.
15. Alvarez E, Nair K, Shelton I et al. Evaluating the Tolerability and Safety of Switching from Rituximab to Ocrelizumab: Infusion Related Reactions in Relapsing Forms of Multiple Sclerosis. Presented at: AAN Annual Meeting 2019; May 7, 2019; Philadelphia, PA, USA. Abstract P 4.2-015.
16. Hauser S, Kappos L, Montablan X et al. Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive Multiple sclerosis. Presented at: AAN Annual Meeting 2019; May 7, 2019; Philadelphia, PA, USA. Abstract P4.2-025.
17. Wormser D, Evershed J, Ferreira G et al. VERISMO: A Post-Marketing Safety Study to Determine the Incidence of All Malignancies and Breast Cancer in Patients With Multiple Sclerosis Treated With Ocrelizumab. Presented at: AAN Annual Meeting 2019; May 7, 2019; Philadelphia, PA, USA. Abstract P 4.2-043.
2. Montalban X, Hauser SL, Kappos L et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med 2017; 376(3): 209-220.
3. Hauser SL, Bar-Or A, Comi G et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med 2017; 376(3): 221-234.
4. Leist T, Reder A, Bermel R et al. One-year interim analysis results of the Phase IIIb CHORDS study evaluating ocrelizumab effectiveness and safety in patients with relapsing-remitting multiple sclerosis who had suboptimal response with prior disease-modifying treatments. Presented at: AAN Annual Meeting 2019; May 7, 2019; Philadelphia, PA, USA. Abstract: S56-007.
5. Cross A, Bennett J, von Büdingen HC et al. Ocrelizumab treatment reduced levels of neurofilament light chain and numbers of B cells in the cerebrospinal fluid of patients with relapsing multiple sclerosis in the OBOE study. Presented at: AAN Annual Meeting 2019; May 7, 2019; Philadelphia, PA, USA. Abstract. S56-008.
6. Naismith R, Coyle P, Saidha S et al. Influence of Gender and Age in Use of Ocrelizumab for PPMS Patients Among US Neurologists. Presented at: AAN Annual Meeting 2019; May 7, 2019; Philadelphia, PA, USA. Abstract P1.2-102.
7. Wolinsky J, Kappos L, Montalban X, Model F. Reduction in 48-Week Confirmed Disability Progression After 5.5 Years of Ocrelizumab Treatment in Patients With Primary Progressive Multiple Sclerosis. Presented at: AAN Annual Meeting 2019; May 7, 2019; Philadelphia, PA, USA. Abstract S3.2-031.
8. Arnold DL, Giovannoni G, Hartung HP et al. Reduced Rate of Brain Atrophy in Patients With PPMS Receiving Ocrelizumab Earlier and Continuously Versus Those Initiating Okrelizumab Later: Results of ORATORIO 5-Year Follow-Up. Presented at: AAN Annual Meeting 2019; May 7, 2019; Philadelphia, PA, USA. Abstract P3.2-042.
9. Hauser SL, Kappos L, Montalban X et al. Long-Term Reduction in 48-Week Confirmed Disability Progression After 5 Years of Ocrelizumab Treatment in Patients With Relapsing Multiple Sclerosis. Presented at: AAN Annual Meeting 2019; May 7, 2019; Philadelphia, PA, USA. Abstract P3.2-054.
10. Giovannoni G, Airas L, Bove R et al. Ocrelizumab Treatment Effect on Upper Limb Function in PPMS Patients with Disability: Subgroup Results of the ORATORIO Study to Inform the ORATORIO-HAND Study Design. Presented at: AAN Annual Meeting 2019; May 7, 2019; Philadelphia, PA, USA. Abstract P3.2-091.
11. Kletzl H, Gibiansky E, Petry C et al. Pharmacokinetics, Pharmacodynamics and Exposure-Response Analyses of Ocrelizumabein Patients With Multiple Sclerosis. Presented at: AAN Annual Meeting 2019; May 7, 2019; Philadelphia, PA, USA. Abstract N4-001.
12. Vollmer T, Alvarez E, Nair K et al. Evaluation of shorter infusion times with ocrelizumabin patients with relapsing-remitting multiple sclerosis. Presented at: AAN Annual Meeting 2019; May 7, 2019; Philadelphia, PA, USA. Abstract P3.2-034.
13. Alimohamadi S, Vollmer B, Nair K et al. Ocrelizumab Safety and Effectiveness in the One Year Treatment of Multiple Sclerosis Compared to Other Disease Modifying Therapies. Presented at: AAN Annual Meeting 2019; May 7, 2019; Philadelphia, PA, USA. Abstract P3.2-053.
14. Moss B, Parrotta E, Baldassari L et al. Real-World Experience with Ocrelizumab. Presented at: AAN Annual Meeting 2019; May 7, 2019; Philadelphia, PA, USA. Abstract P3.2-059.
15. Alvarez E, Nair K, Shelton I et al. Evaluating the Tolerability and Safety of Switching from Rituximab to Ocrelizumab: Infusion Related Reactions in Relapsing Forms of Multiple Sclerosis. Presented at: AAN Annual Meeting 2019; May 7, 2019; Philadelphia, PA, USA. Abstract P 4.2-015.
16. Hauser S, Kappos L, Montablan X et al. Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive Multiple sclerosis. Presented at: AAN Annual Meeting 2019; May 7, 2019; Philadelphia, PA, USA. Abstract P4.2-025.
17. Wormser D, Evershed J, Ferreira G et al. VERISMO: A Post-Marketing Safety Study to Determine the Incidence of All Malignancies and Breast Cancer in Patients With Multiple Sclerosis Treated With Ocrelizumab. Presented at: AAN Annual Meeting 2019; May 7, 2019; Philadelphia, PA, USA. Abstract P 4.2-043.